Daily Sepsis Research Analysis
Analyzed 48 papers and selected 3 impactful papers.
Summary
Three high-impact studies advance sepsis science across mechanisms and care: a multi-omics/mechanistic investigation links inflammation-driven mitochondrial dysfunction and ROS to early lung fibrotic remodeling in sepsis; a preclinical study defines a pathogenic NF-κB/miR-21c/IL-9 feedback loop in septic acute kidney injury; and a large cohort analysis shows that short-term glycemic instability, rather than static glucose, predicts 28-day mortality in sepsis-induced coagulopathy.
Research Themes
- Mitochondrial dysfunction and ROS-driven organ remodeling in sepsis
- Noncoding RNA–cytokine feedback loops in septic acute kidney injury
- Dynamic physiologic trajectories (glycemia) as prognostic markers in sepsis-induced coagulopathy
Selected Articles
1. Inflammation-driven mitochondrial dysfunction and ROS accumulation orchestrate pulmonary fibrotic remodeling in sepsis.
Using integrated multi-omics, animal models, and single-cell/bulk transcriptomics, the authors show that the lung undergoes pronounced immune amplification and mitochondrial dysfunction during early inflammation, activating profibrotic signaling in sepsis. Six ROS-regulatory mitochondrial genes correlate with clinical outcomes, and sustained TNF-α/IL-1β drives ROS overload that reprograms fibroblasts.
Impact: This work elucidates an early, organ-specific mechanism linking inflammation, mitochondrial dysfunction, and ROS to fibrotic remodeling in sepsis, highlighting actionable cytokine and mitochondrial targets.
Clinical Implications: Early modulation of ROS and upstream cytokines (TNF-α/IL-1β), and monitoring of identified mitochondrial genes, could enable prevention or attenuation of post-sepsis pulmonary fibrosis.
Key Findings
- Lung shows stronger immune amplification and more severe mitochondrial dysfunction than other organs during early inflammation, initiating fibrotic signaling in the acute phase.
- Six mitochondrial ROS-regulatory genes (Bcl2l1, Gsr, Msrb3, AA467197, Stom, Sod2) correlate with clinical outcomes in sepsis.
- Persistent TNF-α/IL-1β overexpression drives ROS activation; ROS overload directly damages cells and reprograms fibroblasts in vitro.
- Single-cell and bulk transcriptomics reveal altered immune–parenchymal intercellular communication in septic lungs.
Methodological Strengths
- Integrated multi-omics with animal models plus bulk and single-cell transcriptomics.
- Temporal analyses and cytokine intervention (TNF-α/IL-1β) with in vitro functional validation.
Limitations
- Preclinical design without interventional human validation limits direct clinical translation.
- Potential species and model (inflammation/sepsis) differences; therapeutic efficacy not tested in vivo.
Future Directions: Validate mitochondrial-ROS and cytokine axes in human sepsis cohorts; test ROS/mitochondria-targeted and anti-cytokine interventions to prevent post-sepsis pulmonary fibrosis.
Inflammation-induced pulmonary fibrosis is an irreversible and severe complication that leads to persistent decline in lung function and increased mortality; however, its early pathogenesis is still unclear. This study aimed to systematically elucidate the initiation mechanism of pulmonary fibrosis in the early stages of inflammation. By integrating multi-omics data and animal models, we found that lung exhibits stronger immune amplification and more severe mitochondrial dysfunction in comparison with other organs during inflammation, consequently fibrotic signaling is initiated in the acute phase. Mitochondria-related gene analysis identified six key genes (Bcl2l1, Gsr, Msrb3, AA467197, Stom, and Sod2) involved in the regulation of reactive oxygen species (ROS) metabolism, which were closely associated with clinical outcomes in sepsis. Temporal data and TNF-α/IL-1β intervention experiments revealed that these cytokines are persistently overexpressed in septic lungs, serving as critical drivers of ROS activation. In vitro assays further confirmed that ROS overload directly induces cellular damage and functional reprogramming of fibroblasts.
2. The Positive Feedback Regulation of NF-κB/miR-21c/IL-9 Axis in Septic Acute Kidney Injury.
In LPS-induced septic AKI, NF-κB directly induces miR-21c, whose inhibition mitigates renal dysfunction, histologic injury, apoptosis, and inflammation. miR-21c suppresses IL-9 by targeting its 3'-UTR; IL-9 restoration dampens tubular apoptosis/inflammation and inhibits NF-κB p65 phosphorylation, establishing a pathogenic NF-κB/miR-21c/IL-9 positive feedback loop.
Impact: Defines a tractable, mechanistic feedback loop driving septic AKI and offers dual therapeutic entry points (miR-21c inhibition or IL-9 augmentation).
Clinical Implications: miR-21c antagonism and/or IL-9–based strategies could be developed to reduce renal inflammation and tubular injury in septic AKI.
Key Findings
- NF-κB drives miR-21c upregulation in proximal tubules during LPS-induced septic AKI (validated by ChIP and reporter assays).
- miR-21c inhibition attenuates renal dysfunction, histologic damage, apoptosis, and proinflammatory cytokines; overexpression exacerbates injury.
- miR-21c directly targets IL-9 3'-UTR to suppress IL-9; IL-9 restoration reduces apoptosis/inflammation and inhibits NF-κB p65 phosphorylation, forming a positive feedback loop.
Methodological Strengths
- Comprehensive mechanistic toolkit (ChIP, dual-luciferase, FISH, rescue experiments) across in vivo and in vitro systems.
- Bidirectional perturbation (antagomir and mimic) with functional renal readouts (creatinine, BUN, histology, apoptosis).
Limitations
- LPS model may not capture polymicrobial or hemodynamic aspects of human septic AKI.
- No human tissue or clinical validation; systemic effects of IL-9 modulation not fully characterized.
Future Directions: Validate the NF-κB/miR-21c/IL-9 loop in human AKI biopsies and test miR-21c inhibitors or IL-9 agonism in polymicrobial sepsis models (e.g., CLP) and early-phase trials.
BACKGROUND: Sepsis-associated acute kidney injury (septic AKI) is a leading cause of mortality in critically ill patients. Despite its high prevalence, no specific therapies are currently available, primarily because the molecular mechanisms that sustain renal inflammation and tubular damage remain poorly understood. METHODS: A murine model of LPS-induced septic AKI and cultured murine proximal tubular (BUMPT) cells were used. In vivo, anti-miR-21c or miR-21c mimic was administered via tail vein injection prior to LPS challenge. Molecular interactions were assessed by chromatin immunoprecipitation (ChIP), luciferase reporter assay, qPCR, Western blotting, immunohistochemistry, and fluorescence in situ hybridization. Renal function and injury were evaluated by serum creatinine, blood urea nitrogen (BUN), histopathology, and TUNEL staining. RESULTS: miR-21c was significantly upregulated in renal proximal tubules during LPS-induced septic AKI, coinciding with peak renal dysfunction and tubular damage. This upregulation was driven by NF-κB, as LPS induced p65 nuclear translocation, and pharmacologic inhibition of NF-κB blocked miR-21c induction. ChIP assays confirmed direct binding of p65 to the miR-21c promoter. Subsequent dual-luciferase reporter assays specifically validated the binding site as the functional response element. Functional studies showed that inhibition of miR-21c attenuated kidney injury, reducing serum creatinine and BUN levels, alleviating histological damage, decreasing tubular apoptosis, and suppressing proinflammatory cytokines. Conversely, overexpression of miR-21c exacerbated all injury parameters. Mechanistically, miR-21c directly targeted the 3'-UTR of interleukin-9 (IL-9), as validated by luciferase reporter assay, resulting in reduced IL-9 protein expression. Restoration of IL-9 in tubular cells suppressed LPS-induced apoptosis and inflammation. Importantly, IL-9 overexpression specifically inhibited phosphorylation of NF-κB p65. CONCLUSIONS: Our study identified a pathogenic NF-κB/miR-21c/IL-9 feedback loop that amplified renal inflammation and injury in septic AKI. Targeting miR-21c or enhancing IL-9 signaling may offer novel therapeutic strategies to mitigate kidney damage and improve outcomes in septic patients.
3. Blood Glucose Trajectories and Mortality in Sepsis-Induced Coagulopathy: A Latent Growth Mixture Modeling Analysis.
In 3,762 SIC patients, 24-hour blood glucose trajectories clustered into stable normoglycemia and two fluctuating patterns; the latter independently increased 28-day mortality risk, whereas static admission glucose did not. Glycemic stability provides superior short-term prognostic information in SIC.
Impact: Introduces a dynamic, trajectory-based risk marker that outperforms static glucose values, offering an immediately implementable stratification concept for SIC.
Clinical Implications: Early ICU protocols emphasizing glycemic stability and monitoring trajectory patterns could improve risk stratification and guide targeted interventions in SIC.
Key Findings
- LGMM identified three 24-hour glucose trajectory classes in 3,762 SIC patients: stable normoglycemic, falling-rising, and rising-falling.
- Fluctuating trajectories independently increased 28-day mortality risk versus stable normoglycemia (HR 1.31 and 1.25 after adjustment).
- Static admission glucose was not independently associated with mortality; dynamic stability provided superior prognostic value.
Methodological Strengths
- Large sample size from MIMIC-IV with latent growth mixture modeling to capture dynamic trajectories.
- Multivariable Cox regression with confounder adjustment and sensitivity analyses.
Limitations
- Retrospective single-database study with potential residual confounding and limited generalizability.
- Trajectory window limited to first 24 hours; external validation cohorts are needed.
Future Directions: Prospective validation of trajectory-based glycemic targets in SIC and interventional trials testing glycemic variability reduction strategies.
BACKGROUND: Sepsis-induced coagulopathy (SIC) is a severe complication contributing significantly to mortality in critically ill patients. While hyperglycemia is a known risk factor, the prognostic value of longitudinal blood glucose trajectories specifically in patients with SIC remains poorly understood. METHODS: This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Latent growth mixture modeling (LGMM) was employed to identify and characterize distinct blood glucose trajectory patterns within the first 24 hours of admission. Multivariable Cox regression analysis was performed to explore the association between these trajectories and 28-day mortality. RESULTS: Among 3,762 patients with SIC, LGMM identified three distinct blood glucose trajectory patterns: stable normoglycemic (Class 1), falling-rising (Class 2), and rising-falling (Class 3). After adjusting for confounders, patients with fluctuating trajectories faced a significantly higher risk of 28-day mortality compared to the stable normoglycemic group (Class 2: Hazard Ratio (HR) 1.31, 95% CI 1.05-1.64; Class 3: HR 1.25, 95% CI 1.02-1.54). Static admission blood glucose levels showed no significant independent association with mortality in the adjusted model. CONCLUSION: Distinct dynamic blood glucose trajectories were identified in SIC patients. Glycemic instability, rather than static baseline glucose levels, serves as an independent marker of short-term mortality. Glycemic stability offers superior prognostic value and facilitates improved risk stratification in patients with SIC.